drugset / Trial / NCT02729467
A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the effects of itraconazole, a strong cytochrome P (CYP)3A4 and p-glycoprotein (PgP) inhibitor, and rifampicin, a CYP3A4, uridine 5'-diphospho-glucuronosyltransferase (UGT), and PgP inducer, and an inhibitor of organic anion-transporting polypeptide (OATP), on the single-dose pharmacokinetics (PK) of JNJ-53718678 in healthy adult participants.
Timeline
- Start
- 2016-03
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rilematovir | Other / unclassified | 250 mg | — |
| Subject | Rilematovir | Other / unclassified | 500 mg | — |
| Background | Itraconazole | Small molecule | 200 mg | — |
| Background | Rifampin | Small molecule | 600 mg | — |
Indications
No indication recorded.